<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>EAGER: SARS-CoV-2  Pseudovirus via a novel eukaryotic construction in yeast</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>08/01/2020</AwardEffectiveDate>
<AwardExpirationDate>07/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>225742.00</AwardTotalIntnAmount>
<AwardAmount>225742</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>08070000</Code>
<Directorate>
<Abbreviation>BIO</Abbreviation>
<LongName>Direct For Biological Sciences</LongName>
</Directorate>
<Division>
<Abbreviation>MCB</Abbreviation>
<LongName>Div Of Molecular and Cellular Bioscience</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>David Rockcliffe</SignBlockName>
<PO_EMAI>drockcli@nsf.gov</PO_EMAI>
<PO_PHON>7032927123</PO_PHON>
</ProgramOfficer>
<AbstractNarration>One of the significant impediments in the fight against a disease like COVID-19 is the availability of a safe and effective mimic of the SARS-CoV-2 virus that could be used without the need of very specialized handling and laboratory equipment that could serve as early-stage substitute during technology development. As an early stage substitute the SARS-CoV-2 mimic, or pseudovirus, could serve as a safe, effective tool to create antibodies, develop purification methods, design vaccine candidates, and build diagnostic kits. In the absence of suitable mimics, the nationwide ability to quickly pass/fail ideas is vastly limited. In particular, due to the low number of facilities that are able to safely handle an infectious agent, a strain on infrastructure occurs which ultimately limits the number of teams “in the fight” who may have significant expertise but minimal accommodations.  This project will produce such a safe pseudovirus that could be widely used for the development of materials for this and potentially future pandemics.  In addition, a postdoc will be trained in an interdisciplinary environment.&lt;br/&gt;&lt;br/&gt;The objective of this proposal is to develop a synthetic yeast construct that will serve as a safe (BSL-1), robust and reliable surrogate for SARS-CoV-2 or other infectious agents against which diagnostic and environmental testing assays could be developed and validated.   The key elements of the proposed work are 1) the development of a yeast surface display platform in which the surface density of key proteins normally found on the surface of SARS-CoV-2 can be expressed, 2) the development of a  robust production platform for the biomanufacturing of the yeast pseudovirus, and 3) the validation of the yeast pseudovirus against SARS-CoV-2 to demonstrate that  the yeast pseudovirus can be used as a mimic for SARS-CoV-2 for the development of biologics.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>07/30/2020</MinAmdLetterDate>
<MaxAmdLetterDate>07/30/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.074</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2039528</AwardID>
<Investigator>
<FirstName>Robert</FirstName>
<LastName>Beitle</LastName>
<PI_MID_INIT>R</PI_MID_INIT>
<PI_SUFX_NAME>Jr.</PI_SUFX_NAME>
<PI_FULL_NAME>Robert R Beitle</PI_FULL_NAME>
<EmailAddress>rbeitle@uark.edu</EmailAddress>
<PI_PHON>4795757566</PI_PHON>
<NSF_ID>000210556</NSF_ID>
<StartDate>07/30/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Kaiming</FirstName>
<LastName>Ye</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Kaiming Ye</PI_FULL_NAME>
<EmailAddress>kye@binghamton.edu</EmailAddress>
<PI_PHON>6077775887</PI_PHON>
<NSF_ID>000216479</NSF_ID>
<StartDate>07/30/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Shannon</FirstName>
<LastName>Servoss</LastName>
<PI_MID_INIT>L</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Shannon L Servoss</PI_FULL_NAME>
<EmailAddress>sservoss@uark.edu</EmailAddress>
<PI_PHON>4795754502</PI_PHON>
<NSF_ID>000509188</NSF_ID>
<StartDate>07/30/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Vicki</FirstName>
<LastName>Thompson</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Vicki Thompson</PI_FULL_NAME>
<EmailAddress>vicki.thompson@nowdx.com</EmailAddress>
<PI_PHON>4799664530</PI_PHON>
<NSF_ID>000738004</NSF_ID>
<StartDate>07/30/2020</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>University of Arkansas</Name>
<CityName>Fayetteville</CityName>
<ZipCode>727013124</ZipCode>
<PhoneNumber>4795753845</PhoneNumber>
<StreetAddress>1125 W. Maple Street</StreetAddress>
<StreetAddress2><![CDATA[316 Administration Building]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Arkansas</StateName>
<StateCode>AR</StateCode>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>AR03</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>191429745</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>UNIVERSITY OF ARKANSAS SYSTEM</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>055600001</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[University of Arkansas]]></Name>
<CityName>Fayetteville</CityName>
<StateCode>AR</StateCode>
<ZipCode>727013124</ZipCode>
<StreetAddress><![CDATA[1125 W. Maple Street]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Arkansas</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>AR03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>8011</Code>
<Text>Systems and Synthetic Biology</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7465</Code>
<Text>NANOSCALE BIO CORE</Text>
</ProgramReference>
<ProgramReference>
<Code>7916</Code>
<Text>EAGER</Text>
</ProgramReference>
<ProgramReference>
<Code>9150</Code>
<Text>EXP PROG TO STIM COMP RES</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~225742</FUND_OBLG>
</Award>
</rootTag>
